In this episode, Lance Baldo, MD, discusses the use of MRD testing, T-cell receptor profiling, and how lessons from the COVID-19 pandemic will help shape the future of cancer vaccines. Welcome to another exciting episode of Oncology Overdrive :13 About Baldo :17 The interview 1:20 Tell me about your journey 1:38 Did you question your decision to leave clinical practice for an entrepreneurial venture? 2:36 What does Adaptive Biotechnologies do? 3:43 What is Minimal Residual Disease (MRD) testing and how is it used? 4:27 Are you looking only at hematologic malignancies? 5:35 How are experts using MRD testing in clinical practice? 6:31 Why do you think MRD testing is important in treating cancers? 7:24 Is Adaptive working on drug discovery and development related to MRD testing? 9:20 Personalized care and how real life feels like science fiction 12:02 Doing what’s best for the patient 15:33 Tell me about T-cell receptor profiling 18:02 Tell me about neo-antigen-based therapy 21:10 Are these types of technologies available outside of large, academic institutions? 22:49 Has COVID impacted the way you and your team think about implementing therapies and innovation? 25:03 Do you think what we’ve learned over the last year will help with the creation of future cancer vaccines? 29:59 If we spoke again in 10 years, what would you hope to have done? 31:25 Baldo’s take-home message 37:42 Where to find Baldo 38:57 Lance Baldo, MD, is chief medical officer of Adaptive Biotechnologies. We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow us on Twitter @HemOncToday and @ShikhaJainMD. Baldo can be reached on LinkedIn, via email at [email protected] and at www.adaptivebiotech.com.    Disclosures: Baldo is chief medical officer of Adaptive Biotechnologies. Jain reports she is a paid freelance writer for Lippincott.

Ver todos los episodios